Insulin
FDA approves subcutaneous Merilog for glycemic control in diabetes
The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes.
‘Alternative’ markers of insulin resistance can predict osteoarthritis
Surrogate measures of insulin resistance, based on the triglyceride-glucose index, can be used to predict the development of osteoarthritis, according to data published in Scientific Reports.
Although superior to other insulin therapies, hybrid closed-loop systems differ in efficacy
Hybrid closed-loop systems outperformed other types of subcutaneous insulin treatment for diabetes, but some systems were more efficient than others, according to results published in Diabetes/Metabolism Research and Reviews.
Pioglitazone added to insulin increases ischemic heart disease risk in type 2 diabetes
Patients with type 2 diabetes uncontrolled by metformin who received pioglitazone and insulin demonstrated increased risk for ischemic heart disease, according to findings published in the Journal of Diabetes and Its Complications.
Diabetes inequities persist worldwide, especially for low-, middle-income countries
From 1990 to 2022, diabetes prevalence rose greatly, but for the most part, treatment did not increase at all or sufficiently, especially in low- and middle-income countries, researchers reported in The Lancet.
Duodenal mucosal renewal plus semaglutide may lower HbA1c long term without insulin use
A novel duodenal mucosal renewal procedure followed by once-weekly semaglutide could allow adults with type 2 diabetes to maintain glycemic control without insulin therapy, according to a speaker.
FTC files administrative complaint vs. PBMs alleging artificially inflated insulin prices
The Federal Trade Commission announced it has filed an administrative complaint against three pharmacy benefit managers alleging “anticompetitive and unfair” rebate practices that have artificially inflated the price of insulin drugs.
Sotagliflozin improves time in range in basal insulin-treated type 2 diabetes
In patients with basal insulin-treated type 2 diabetes, sotagliflozin was associated with greater time in range compared with placebo at 18 weeks, researchers reported at the European Association for the Study of Diabetes Annual Meeting.
Tirzepatide tied to lower odds for diabetic retinopathy, pancreatitis than GLP-1s
Tirzepatide is associated with similar odds for gastrointestinal adverse events and a lower likelihood for diabetic retinopathy and pancreatitis compared with GLP-1 receptor agonists, according to a presenter.
QWINT: Once-weekly basal insulin noninferior to daily insulins in type 2 diabetes
A novel once-weekly basal insulin conferred noninferior HbA1c reductions compared with daily insulins for insulin-naive adults with type 2 diabetes and those who switched from daily injections, according to topline results from two trials.